Clinical trial · people

Melanotan II: darker skin in 2 of 3 men in a small phase I trial

Checked against the paper Clinical trialPublished by PepVault

The takeaway

This early human trial found that 5 low Melanotan II doses darkened skin in 2 of 3 men, with mild nausea at most doses, spontaneous erections after dosing, and sleepiness and fatigue in one man at the top dose.

Kind
Clinical trial
Studied in
People
Number studied
3
Published
1996
Journal
Life Sci

What they tested

The team wanted to see whether Melanotan II is safe enough to give to people, what side effects it causes, and whether it darkens human skin.

How the study was done

A small, single-blind, placebo-controlled phase I trial in 3 healthy male volunteers. Over 2 weeks, they got shots under the skin on weekdays, switching each day between Melanotan II and saline (salt water), with the dose stepped up from a starting 0.01 mg/kg.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Melanotan II? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Two men reached 0.03 mg/kg and one reached 0.025 mg/kg. At 0.03 mg/kg, one of the two men had Grade II sleepiness and fatigue. Mild nausea that needed no anti-nausea medicine showed up at most dose levels. The men also had a pattern of stretching and yawning that seemed to line up with spontaneous erections, which came and went for 1-5 hours after a dose depending on the dose. One week after the last dose, 2 men had darker skin on the face, upper body and buttocks, judged both by eye and by a reflectance measurement. The team named 0.025 mg/kg/day as the single dose to use in later phase I studies.

What it doesn’t show

With only 3 men, no women and single blinding, this trial can't say how common these effects are or how strong the tanning is across people. It covered just 2 weeks of dosing, so it doesn't speak to longer-term safety.

The paper

Dorr et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996.

The compounds

More studies on Melanotan II

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Melanotan II? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo